Stock Analysis
Penumbra, Inc.PEN
P/E 78.70×· 5Y range 53.97–2,052.17×· 25th percentile of history
Sector: Healthcare · Industry: Surgical & Medical Instruments & Apparatus
AnalystsHold20 analystsP/E 78.7× sits at the 25th percentile of its 5.0513347022587265-year history.
Cash covers 310% of debt · Q2 2026.
PMP Verdict
High quality, fairly valued
Strengths
- Financial Health100
- Growth90
Strong fundamentals at a reasonable valuation.
Bull Case
- ✓Piotroski F-Score 7/9 — high earnings quality
- ✓Altman Z 18.6 — safe-zone balance sheet
- ✓Revenue CAGR 17.1% — durable top-line growth
What's happening with PEN
Profile
Strong financial health, growth and earnings quality; valuation and moat lag behind.
How is each axis scored?
- Valuation37/100 · Weak
- P/E vs own history (25th pct)20/25
- FCF yield (1.7%)5/25
- P/S (8.4x)12/25
- EV/EBIT (65.1x)0/25
- Growth90/100 · Strong
- Revenue CAGR (17.1%)20/25
- Net income CAGR (140.8%)25/25
- EPS CAGR 5Y (138.6%)25/25
- Fwd implied growth (16.6%)20/25
- Profitability56/100 · Moderate
- ROIC (13.6%)12/25
- ROE (10.5%)12/25
- Net margin (10.7%)20/25
- Operating margin (12.4%)12/25
- Financial Health100/100 · Strong
- Altman Z (18.57)25/25
- Current ratio (5.75)25/25
- Interest coverage (no interest expense)25/25
- Net cash / debt (Net cash)25/25
- Quality87/100 · Strong
- Piotroski F (7/9)22/25
- Beneish M (-2.49)20/25
- FCF conversion (134%)25/25
- Margin stability (σ 5.7%)20/25
- Moat40/100 · Weak
- ROIC >12% years (1/10 yrs)0/25
- Median gross margin (64.7%)25/25
- FCF-positive years (6/10 yrs)10/25
- Worst-year net margin (worst -2.8%)5/25
Risk Flags
- ⚠2 loss-making years in recent history
About Penumbra, Inc.
Domiciled in the US, Penumbra designs, manufactures, and markets an array of thrombectomy and embolization devices and equipment to mechanically remove blood clots. Show more
The firm sells mainly to hospitals and physicians. These minimally invasive devices are primarily used in the acute care setting for patients with stroke, pulmonary embolism, deep vein thrombosis, cranial aneurysms, and other vascular diseases.
Headquarters: ALAMEDA, CA · Employees: 4,700 · Website ↗
Price History
Weekly Candlestick Chart — up to 5Y
Key Metrics
Financial snapshot · Tap any metric for its definition and grade
TTM Snapshot
trailing twelve months · YoYValuation
37DP/E (TTM)78.7xD
Grade D: ExpensivePrice / TTM EPS (own statements) — vs own 5Y history: 54.0x–2052.2x · 25th pct
P/FCF58.6xD
Grade D: ExpensivePrice / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative
FCF Yield1.7%C
Grade C: LowTTM (OCF − CapEx) / Market Cap — vs own 5Y history: -1.6%–1.8% · 93rd pct
P/S (TTM)8.40xC
Grade C: ExpensivePrice / TTM Revenue (own statements) — vs own 5Y history: 5.6x–15.3x · 39th pct
EV/EBIT65.1xD
Grade D: ExpensiveEnterprise value / TTM EBIT (D&A not in our data) — capital-structure neutral — vs own 5Y history: 64.0x–66.4x · 58th pct
EV/Sales8.3xC
Grade C: ExpensiveEnterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E67.5xD
Grade D: ExpensivePrice / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B Ratio8.26xD
Grade D: Very expensivePrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio9.90D
Grade D: ExpensiveFinnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield—
TTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio—
Dividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Profitability
56CROIC13.6%C
Grade C: AverageNOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROE10.5%C
Grade C: AverageReturn on Equity. Neg. equity = heavy buybacks
ROA8.6%C
Grade C: AverageReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin10.7%A
Grade A: HighNet Income / Revenue
Operating Margin12.4%C
Grade C: AverageTTM EBIT / TTM Revenue
Gross Margin67.8%A
Grade A: PremiumGross Profit / Revenue
FCF Margin14.3%C
Grade C: AverageFCF / Revenue
True FCF Margin10.4%C
Grade C: AverageTTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost
Growth
90A+Revenue CAGR17.1%A
Grade A: HighCompound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR140.8%A
Grade A: HighCompound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)138.6%A
Grade A: HighCompound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Implied EPS Growth16.6%C
Grade C: MedAnalyst forward EPS (normalized basis) vs our GAAP TTM EPS — different bases, so extreme values usually mark cyclically depressed TTM earnings, not real growth
Dilution (5Y)+4.9%C
Grade C: DilutiveShare count change over 5Y
SBC / Net Income37.0%D
Grade D: HighStock-based comp/Net income. >30% = dilution risk
SBC / Revenue4.0%C
Grade C: MedTTM stock-based comp / TTM Revenue
Financial Health
100A+Altman Z-Score18.57A
Grade A: SafeBankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio5.75xA
Grade A: HighCurrent Assets/Liabilities
Quick Ratio3.63xA
Grade A: High(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage—
EBIT/Interest. >10 Strong
Debt RepaymentNet CashA
Grade A: FastYears to repay net debt via FCF
Net Debt/EBITNet CashA
Grade A: LowLeverage. <2x Low, >4x High
Debt/Equity0.14xA
Grade A: LowDebt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt3.10xA
Grade A: CoveredCash covers how much of total debt. >1 = could repay all debt from cash
Quality
87APiotroski F-Score7/9A
Grade A: StrongFinancial strength 0–9. >7 Strong
Beneish M-Score-2.49A
Grade A: SafeEarnings manipulation risk. < -2.22 Safe
FCF Conversion134.4%A
Grade A: StrongFCF / Net Income
Margin Stability5.7%A
Grade A: StableEBIT margin std deviation. Lower = stable
Capex / Revenue4.1%A
Grade A: Asset-lightTTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover0.81xC
Grade C: AverageRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
Insider Transactions
SEC Form 4 · 8 recordsP/S codes are the directional signal; grants, option exercises and tax withholding carry none. Form 4 doesn't flag 10b5-1 plans — scheduled sales may appear within open-market sells.
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Narayan Shruthi Filed | Narayan Shruthi | Tax withholding | -1230 | |
Narayan Shruthi Filed | Narayan Shruthi | Grant / award | +3.1K | |
Elsesser Adam Filed | Elsesser Adam | Gift | -77000 | |
Grewal Harpreet Filed | Grewal Harpreet | SellOpen market sale | -100 | |
Narayan Shruthi Filed | Narayan Shruthi | Tax withholding | -117 |
Show 3 more filingsShow fewer filings
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Shiu Lambert Filed | Shiu Lambert | Tax withholding | -150 | |
Yuen Maggie Filed | Yuen Maggie | Tax withholding | -186 | |
Roberts Johanna Filed | Roberts Johanna | Tax withholding | -186 |
More metrics — Moat, Per Share, Balance Sheet, MarketHide additional metrics
Moat
40D+ROIC >12% Years1/10 yrsD
Grade D: WeakShare of completed fiscal years with ROIC > 12% — measures multi-year capital-return durability
Gross Margin (Med.)64.7%A
Grade A: DurableMedian annual gross margin across available fiscal years — pricing-power durability
FCF-Positive Years6/10 yrsD
Grade D: WeakShare of completed fiscal years with positive free cash flow
Net Margin Floor-2.8%D
Grade D: WeakWeakest annual net margin across completed fiscal years — recession/downcycle resilience
Per Share
EPS (TTM)$4.08
Own TTM net income / shares — same earnings basis as P/E
Cash / Share$16.73
Cash & short-term investments per share (Finnhub)
Book Value / Share$38.86
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt$212.71M
Total debt obligations (short + long term)
Cash & Equiv.$658.79M
Cash and short-term investments
Net Debt$-446.08MA
Grade A: Net CashTotal Debt minus Cash. Negative = Net Cash position
Total Equity$1.53B
Shareholders' equity (book value)
Asset / Liability4.45xA
Grade A: SolidTotal Assets / Total Liabilities
Market
Market Cap$12.64B
Current Market Capitalization
Beta0.69B
Grade B: DefensivePrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Financials as of Jun 2026 · Ratio snapshot Oct 17, 2026
Key Insights: Penumbra, Inc. (PEN)
Penumbra, Inc. meets 7 of 9 Piotroski F-Score criteria, placing its fundamental strength in the top tier of US-listed stocks. Altman Z-Score of 18.57 sits comfortably in the safe zone (≥ 2.99), indicating low bankruptcy risk. Beneish M-Score of -2.49 suggests a low likelihood of earnings manipulation.
- Revenue has compounded at roughly 17% annually, with net income growing about 141% per year — a strong growth profile.
- Company is effectively debt-free after netting cash.
- Penumbra, Inc. posted a net loss in 2 of 10 available completed fiscal years (2016–2025).
See how PEN ranks on the Capex Tracker — top 50 capital spenders compared.
Recent Market Moves
See all PEN moves →| Date | Session | Price | Move | Z-Score |
|---|---|---|---|---|
| Oct 15 | After-hours | 328.98 | +2.77% | 10.13 |
| Oct 14 | Pre-market | 317.18 | -0.88% | -3.40 |
| Oct 9 | Regular | 319.24 | +0.54% | 2.03 |
| Oct 9 | After-hours | 319.40 | +0.59% | 2.22 |
| Sep 30 | After-hours | 314.50 | -1.37% | -3.60 |
Frequently Asked Questions about PEN
What is the current Penumbra, Inc. (PEN) stock price?
PEN is trading at $320.86 at the last market close, down 0.11% on the session. PreMarketPrice tracks PEN pre-market, intraday and after-hours prices.
Is PEN stock a buy right now?
PreMarketPrice's quantitative model rates Penumbra, Inc.'s financial health at 100/100. This is a data-driven snapshot of fundamentals, not investment advice.
Is PEN stock overvalued?
Penumbra, Inc. trades at a trailing P/E of 78.7 and our valuation score rates it 37/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does Penumbra, Inc. report earnings?
No confirmed earnings date is currently scheduled for PEN. The Earnings section lists recent reports and updates as dates are announced.
What sector does Penumbra, Inc. operate in?
Penumbra, Inc. operates in the Healthcare sector, within the Surgical & Medical Instruments & Apparatus industry. The Related Stocks section lists sector peers for comparison.
What does Penumbra, Inc. do?
Domiciled in the US, Penumbra designs, manufactures, and markets an array of thrombectomy and embolization devices and equipment to mechanically remove blood clots.
About Penumbra, Inc. (PEN) Stock
Penumbra, Inc. (PEN) is a US-listed stock operating in the Healthcare sector, specifically the Surgical & Medical Instruments & Apparatus industry. As of the latest update, Penumbra, Inc. is trading at $320.86, down 0.11% on the day with a market capitalization of $12.6 billion. The financial health score for PEN is 100/100, which indicates excellent financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for PEN stock.
PEN Stock Analysis & Key Metrics
On PreMarketPrice, you can track Penumbra, Inc. (PEN) across multiple dimensions:
- Pre-market price & movement: Real-time PEN stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for PEN with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for Penumbra, Inc. across multiple reporting periods.
- Financial health score: A composite score of 100/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for PEN.
- Sector peers: Compare PEN against 6 other healthcare stocks on key financial metrics.
Is PEN a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate Penumbra, Inc. (PEN) as an investment. The financial health score of 100/100 suggests excellent financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.Penumbra, Inc. (PEN) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.